Drug–Drug Interactions with the NS3/4A Protease Inhibitor Simeprevir

Clinical Pharmacokinetics

Volumn 55, Issue 2, 2016, Pages 197-208

  Ouwerkerk Mahadevan, Sivi ^a   Snoeys, Jan ^a   Peeters, Monika ^b   Beumont Mauviel, Maria ^b   Simion, Alexandru ^b  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^b JANSSEN RESEARCH FOUNDATION   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CAFFEINE; CYCLOSPORIN; CYTOCHROME P450 1A2 INHIBITOR; CYTOCHROME P450 3A INDUCER; CYTOCHROME P450 3A INHIBITOR; DARUNAVIR; DARUNAVIR PLUS RITONAVIR; DEXTROMETHORPHAN; DIGOXIN; EFAVIRENZ; ERYTHROMYCIN; ESCITALOPRAM; ETHINYLESTRADIOL; METHADONE; MIDAZOLAM; NORETHISTERONE; OMEPRAZOLE; ORAL CONTRACEPTIVE AGENT; RALTEGRAVIR; RIFAMPICIN; RILPIVIRINE; RITONAVIR; ROSUVASTATIN; SIMEPREVIR; SIMVASTATIN; TACROLIMUS; TENOFOVIR; UNINDEXED DRUG; WARFARIN; PROTEINASE INHIBITOR; VIRAL PROTEIN;

AREA UNDER THE CURVE; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG INTERACTION; DRUG METABOLISM; DRUG POTENTIATION; HUMAN; MAXIMUM PLASMA CONCENTRATION; MINIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; REVIEW; ANTAGONISTS AND INHIBITORS;

DRUG INTERACTIONS; HUMANS; PROTEASE INHIBITORS; SIMEPREVIR; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84958757471     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-015-0314-y     Document Type: Review

References (52)

1. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med. 2001;345(1):41–52.
2. Ghany MG, Nelson DR, Strader DB, et al. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011;54(4):1433–44.
3. American Association for the Study of Liver Diseases, Infectious Diseases Society of America, International Antiviral Society—USA. Recommendations for testing, managing, and treating hepatitis C [online]. http://www.hcvguidelines.org. Published 21 March 2014. Accessed 20 Aug 2014.
4. Jacobson IM, Dore GJ, Foster GR, et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2014;384(9941):403–13.
5. European Medicines Agency. OLYSIO 150 mg hard capsules: summary of product characteristics [online]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/002777/WC500167869.pdf. Published 06 Apr 2014. Accessed 30 Jun 2014.
6. Fried MW, Buti M, Dore GJ, et al. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naive genotype 1 hepatitis C: the randomized PILLAR study. Hepatology. 2013;58(6):1918–29.
7. Forns X, Lawitz E, Zeuzem S, et al. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial. Gastroenterology. 2014;146(7):1669–79.
8. Zeuzem S, Berg T, Gane E, et al. Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial. Gastroenterology. 2014;146(2):430–41.
9. Manns M, Marcellin P, Poordad F, et al. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2014;384(9941):414–26.
10. Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet. 2014;384(9956):1756–65.
11. OLYSIO (simeprevir) capsules: package insert. Titusville: Janssen Pharmaceuticals, Inc; 2013. https://www.olysio.com/shared/product/olysio/prescribing-information.pdf. Published Nov 2013. Accessed 30 Jun 2014.
12. Dieterich D, Rockstroh J, Orkin C, et al. Simeprevir (TMC435) plus pegIFN/ribavirin in HCV genotype-1/HIV coinfection (study no. C212) [oral presentation]. Presented at: 21st conference on retroviruses and opportunistic infections (CROI); March 3–6, 2014; Boston, MA, USA.
13. Moreno C, Hezode C, Marcellin P, et al. Once-daily simeprevir (TMC435) with peginterferon/ribavirin in treatment-naïve or treatment-experienced chronic HCV genotype 4-infected patients: final results of a phase III trial [poster]. Presented at: 49th annual meeting of the European Association for the Study of the Liver (EASL); April 9–13, 2014; London.
14. Fried MW, Buti M, Dore GJ. TMC435 in combination with peginterferon and ribavirin in treatment-naive HCV genotype 1 patients: final analysis of the PILLAR phase IIB study [oral presentation]. Presented at: 62nd annual meeting of the American Association for the Study of Liver Diseases (AASLD); November 4–8, 2011; San Francisco, CA, USA.
15. Burgess S, Partovi N, Yoshida EM, et al. Drug interactions with direct-acting antivirals for hepatitis C: implications for HIV and transplant patients. Ann Pharmacother. 2015;49(6):674–87.
16. Reesink HW, Fanning GC, Farha KA, et al. Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients. Gastroenterology. 2010;138(3):913–21.
17. Ouwerkerk-Mahadevan S, Simion A, Mortier S, et al. The effect of food and different meal types on the bioavailability of simeprevir (TMC435), an HCV protease inhibitor in clinical development [poster no. 0_20]. Presented at: 8th international workshop on clinical pharmacology of hepatitis therapy; June 26–27, 2013; Cambridge, MA, USA.
18. Simion A, Mortier S, Peeters M, et al. Pharmacokinetics of simeprevir (TMC435) in volunteers with severe renal impairment [abstract no. O_03_PK]. Rev Antiviral Ther Infec Dis. 2013;6:5.
19. Ouwerkerk-Mahadevan S, Simion A, Spittaels K, et al. Pharmacokinetics of simeprevir (TMC435) in volunteers with moderate or severe hepatic impairment [abstract no. O_04_PK]. Rev Antiviral Ther Infec Dis. 2013;6:6.
20. Huisman MT, Snoeys J, Monbaliu J, et al. In vitro studies investigating the mechanism of interaction between TMC435 and hepatic transporters [poster]. Presented at: 61st annual meeting of the American Association for the Study of Liver Disease (AASLD); October 29 to November 2, 2010; San Francisco, CA, USA.
21. Sekar V, Verloes R, Meyvisch P, et al. Evaluation of metabolic interactions for TMC435 via cytochrome P450 (CYP) enzymes in healthy volunteers [poster]. Presented at: 45th annual meeting of the European Association for the Study of the Liver (EASL); April 14–18, 2010; Vienna.
22. de Kanter CT, Drenth JP, Arends JE, et al. Viral hepatitis C therapy: pharmacokinetic and pharmacodynamic considerations. Clin Pharmacokinet. 2014;53(5):409–27.
23. Dickinson L, Khoo S, Back D. Differences in the pharmacokinetics of protease inhibitors between healthy volunteers and HIV-infected persons. Curr Opin HIV AIDS. 2008;3(3):296–305.
24. Morcos PN, Moreira SA, Brennan BJ, et al. Influence of chronic hepatitis C infection on cytochrome P450 3A4 activity using midazolam as an in vivo probe substrate. Eur J Clin Pharmacol. 2013;69(10):1777–84.
25. Jetter A, Fatkenheuer G, Frank D, et al. Do activities of cytochrome P450 (CYP)3A, CYP2D6 and P-glycoprotein differ between healthy volunteers and HIV-infected patients? Antivir Ther. 2010;15(7):975–83.
26. Ouwerkerk-Mahadevan S, Sekar V, Peeters M, et al. The pharmacokinetic interactions of HCV protease inhibitor TMC435 with rilpivirine, tenofovir, efavirenz or raltegravir in healthy volunteers [presentation]. Presented at: 19th conference on retroviruses and opportunistic infections (CROI); March 5–8, 2012; Seattle, WA, USA.
27. ® (ribavirin USP) tablets: package insert. Warrendale: Kadmon Pharmaceuticals, LLC; 2012. https://kadmon.com/files/ribasphere-tablets-pi.pdf. Published Feb 2012. Accessed 10 Aug 2014.
28. Zhang H, Cui D, Wang B, et al. Pharmacokinetic drug interactions involving 17alpha-ethinylestradiol: a new look at an old drug. Clin Pharmacokinet. 2007;46(2):133–57.
29. Korhonen T, Turpeinen M, Tolonen A, et al. Identification of the human cytochrome P450 enzymes involved in the in vitro biotransformation of lynestrenol and norethindrone. J Steroid Biochem Mol Biol. 2008;110(1–2):56–66.
30. Ouwerkerk-Mahadevan S, Simion A, Spittaels K, et al. No pharmacokinetic interaction between the investigational HCV protease inhibitor simeprevir (TMC435) and an oral contraceptive containing ethinylestradiol and norethindrone [poster]. Presented at: 63rd annual meeting of the American Association for the Study of Liver Diseases (AASLD); November 9–13, 2012; Boston, MA, USA.
31. Tischer S, Fontana RJ. Drug–drug interactions with oral anti-HCV agents and idiosyncratic hepatotoxicity in the liver transplant setting. J Hepatol. 2014;60(4):872–84.
32. Ouwerkerk-Mahadevan S, Simion A, Mortier S, et al. No clinically significant interaction between the investigational HCV protease inhibitor simeprevir (TMC435) and the immunosuppressive agents cyclosporine and tacrolimus [oral presentation]. Presented at: 63rd annual meeting of the American Association for the Study of Liver Diseases (AASLD); November 9–13, 2012; Boston, MA, USA.
33. Pavlovic Z, Delic D, Maric NP, et al. Depressive symptoms in patients with hepatitis C treated with pegylated interferon alpha therapy: a 24-week prospective study. Psychiatr Danub. 2011;23(4):370–7.
34. Spina E, Trifiro G, Caraci F. Clinically significant drug interactions with newer antidepressants. CNS Drugs. 2012;26(1):39–67.
35. Ouwerkerk-Mahadevan S, Beumont-Mauviel M, Simion A, et al. The pharmacokinetic interaction between the investigational HCV NS3/4A protease inhibitor TMC435 and escitalopram [poster]. Presented at: 62nd annual meeting of the American Association for the Study of Liver Disease (AASLD); November 4–8, 2011; San Francisco, CA, USA.
36. Ward JW, Valdiserri RO, Koh HK. Hepatitis C virus prevention, care, and treatment: from policy to practice. Clin Infect Dis. 2012;55(Suppl 1):S58–63.
37. Totah RA, Allen KE, Sheffels P, et al. Enantiomeric metabolic interactions and stereoselective human methadone metabolism. J Pharmacol Exp Ther. 2007;321(1):389–99.
38. Kharasch ED, Bedynek PS, Park S, et al. Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: I. Evidence against CYP3A mediation of methadone clearance. Clin Pharmacol Ther. 2008;84(4):497–505.
39. Ouwerkerk-Mahadevan S, Beumont-Mauviel M, De Smedt G, et al. The pharmacokinetic interaction between the investigational NS3/4A HCV protease inhibitor TMC435 and methadone [poster]. Presented at: 62nd annual meeting of the American Association for the Study of Liver Disease (AASLD); November 4–8, 2011; San Francisco, CA, USA.
40. European Medicines Agency. Daklinza 30 mg film-coated tablets: summary of product characteristics [online]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003768/WC500172848.pdf. Published 15 Sept 2014. Accessed 18 Sept 2014.
41. Ouwerkerk-Mahadevan S, Sekar V, Simion A, et al. The pharmacokinetic interactions of the HCV protease inhibitor simeprevir (TMC435) with HIV antiretroviral agents in healthy volunteers [poster]. Presented at: IDWeek; October 17–21, 2012; San Diego, CA, USA.
42. Sovaldi™ (sofosbuvir) tablets: package insert. Foster City: Gilead Sciences, Inc; 2013. https://www.gilead.com/~/media/Files/pdfs/medicines/liver-disease/sovaldi/sovaldi_pi.pdf. Published Dec 2013. Accessed 10 Aug 2014.
43. Zhou SF, Xue CC, Yu XQ, et al. Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther Drug Monit. 2007;29(6):687–710.
44. Rittweger M, Arasteh K. Clinical pharmacokinetics of darunavir. Clin Pharmacokinet. 2007;46(9):739–56.
45. Ouwerkerk-Mahadevan S, Sekar V, Simion A, et al. The pharmacokinetic interactions of the HCV protease inhibitor simeprevir (TMC435) with HIV antiretroviral agents in healthy volunteers [poster]. Presented at: IDWeek; October 17–21, 2012; San Diego, CA, USA.
46. Choi MK, Jin QR, Choi YL, et al. Inhibitory effects of ketoconazole and rifampin on OAT1 and OATP1B1 transport activities: considerations on drug–drug interactions. Biopharm Drug Dispos. 2011;32(3):175–84.
47. Baciewicz AM, Chrisman CR, Finch CK, et al. Update on rifampin, rifabutin, and rifapentine drug interactions. Curr Med Res Opin. 2013;29(1):1–12.
48. Naidoo P, Chetty VV, Chetty M. Impact of CYP polymorphisms, ethnicity and sex differences in metabolism on dosing strategies: the case of efavirenz. Eur J Clin Pharmacol. 2014;70(4):379–89.
49. Weiss J, Theile D, Ketabi-Kiyanvash N, et al. Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors. Drug Metab Dispos. 2007;35(3):340–4.
50. Ouwerkerk-Mahadevan S, Simion A, Peeters M, et al. Summary of pharmacokinetic drug–drug interactions for simeprevir (TMC435), a hepatitis C virus NS3/4A protease inhibitor [poster]. Presented at: 14th European AIDS Conference (EACS); October 16–19, 2013; Brussels.
51. Chauvin B, Drouot S, Barrail-Tran A, et al. Drug–drug interactions between HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors. Clin Pharmacokinet. 2013;52(10):815–31.
52. Zhelyazkova-Savova M, Gancheva S, Sirakova V. Potential statin–drug interactions: prevalence and clinical significance. Springerplus. 2014;3:168.